

Richard Buus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4017108/publications.pdf>

Version: 2024-02-01

24
papers

1,141
citations

686830

13
h-index

580395

25
g-index

26
all docs

26
docs citations

26
times ranked

2308
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. <i>European Journal of Cancer</i> , 2022, 164, 52-61.	1.3	0
2	Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 126-135.	0.8	69
3	3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 847-859.	0.4	7
4	Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®. <i>Npj Breast Cancer</i> , 2021, 7, 15.	2.3	11
5	Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 295-305.	1.1	1
6	Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study. <i>Clinical Cancer Research</i> , 2020, 26, 623-631.	3.2	10
7	Real-time <i>ex vivo</i> perfusion of human lymph nodes invaded by cancer (REPLICANT): a feasibility study. <i>Journal of Pathology</i> , 2020, 250, 262-274.	2.1	5
8	Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4682-4687.	3.2	22
9	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 377-386.	1.1	61
10	Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors. <i>Clinical Cancer Research</i> , 2019, 25, 7485-7496.	3.2	18
11	Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 42.	2.3	13
12	Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. <i>British Journal of Cancer</i> , 2019, 120, 247-255.	2.9	13
13	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 545.	3.4	246
14	Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 103.	2.2	7
15	Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease. <i>Clinical Cancer Research</i> , 2016, 22, 2405-2416.	3.2	41
16	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw149.	3.0	165
17	PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. <i>Nature Medicine</i> , 2016, 22, 1303-1313.	15.2	188
18	Class II phosphoinositide 3-kinase C2î2 regulates a novel signaling pathway involved in breast cancer progression. <i>Oncotarget</i> , 2016, 7, 18325-18345.	0.8	25

#	ARTICLE	IF	CITATIONS
19	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2763-2770.	3.2	36
20	Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms. <i>Current Pharmaceutical Design</i> , 2013, 19, 680-686.	0.9	8
21	Genetic and epigenetic regulation of phosphoinositide 3-kinase isoforms. <i>Current Pharmaceutical Design</i> , 2013, 19, 680-6.	0.9	5
22	Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4928-4937.	3.2	92
23	Deubiquitinase Activities Required for Hepatocyte Growth Factor-Induced Scattering of Epithelial Cells. <i>Current Biology</i> , 2009, 19, 1463-1466.	1.8	50
24	Regulation of ErbB2 Receptor Status by the Proteasomal DUB POH1. <i>PLoS ONE</i> , 2009, 4, e5544.	1.1	42